Stockreport

ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF -- Objective response rate (ORR) of 74% across all tested dose levels of ZL-1310 in patients with recurrent extensive-stage small cell lung cancer (SCLC)-- Favorable pha [Read more]